Keros Therapeutics, Inc. (KROS)
10.78
-0.25
(-2.27%)
USD |
NASDAQ |
Aug 24, 16:00
10.79
+0.01
(+0.09%)
After-Hours: 20:00
Keros Therapeutics Max Drawdown (5Y) : 88.46% for July 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| July 31, 2026 | 88.46% |
| June 30, 2026 | 88.46% |
| May 31, 2026 | 88.46% |
| April 30, 2026 | 88.46% |
| March 31, 2026 | 88.46% |
| February 28, 2026 | 88.46% |
| January 31, 2026 | 88.46% |
| December 31, 2025 | 88.46% |
| November 30, 2025 | 88.46% |
| October 31, 2025 | 88.46% |
| September 30, 2025 | 88.46% |
| August 31, 2025 | 88.46% |
| July 31, 2025 | 88.46% |
| June 30, 2025 | 88.46% |
| May 31, 2025 | 88.46% |
| April 30, 2025 | 88.46% |
| March 31, 2025 | 87.73% |
| February 28, 2025 | 87.73% |
| January 31, 2025 | 87.41% |
| December 31, 2024 | 81.10% |
| November 30, 2024 | 68.54% |
| October 31, 2024 | 68.54% |
| September 30, 2024 | 68.54% |
| August 31, 2024 | 68.54% |
| July 31, 2024 | 68.54% |
| Date | Value |
|---|---|
| June 30, 2024 | 68.54% |
| May 31, 2024 | 68.54% |
| April 30, 2024 | 68.54% |
| March 31, 2024 | 68.54% |
| February 29, 2024 | 68.54% |
| January 31, 2024 | 68.54% |
| December 31, 2023 | 68.54% |
| November 30, 2023 | 68.54% |
| October 31, 2023 | 68.54% |
| September 30, 2023 | 68.54% |
| August 31, 2023 | 68.54% |
| July 31, 2023 | 68.54% |
| June 30, 2023 | 68.54% |
| May 31, 2023 | 68.54% |
| April 30, 2023 | 68.54% |
| March 31, 2023 | 68.54% |
| February 28, 2023 | 68.54% |
| January 31, 2023 | 68.54% |
| December 31, 2022 | 68.54% |
| November 30, 2022 | 68.54% |
| October 31, 2022 | 68.54% |
| September 30, 2022 | 68.54% |
| August 31, 2022 | 68.54% |
| July 31, 2022 | 68.54% |
| June 30, 2022 | 68.54% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Incyte Corp. | 58.51% |
| Nurix Therapeutics, Inc. | 91.53% |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Anika Therapeutics, Inc. | 83.15% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -35.56 |
| Beta (5Y) | 0.9857 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 69.90% |
| Historical Sharpe Ratio (5Y) | -0.3789 |
| Historical Sortino (5Y) | -0.5382 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 32.29% |